Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors

摘要

A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone.

主权项

1. A method for inhibiting the proliferation of carcinoma cells that express an EGF receptor, comprising
(a) exposing the cells to an anti-EGF receptor antibody trastuzumab, and (b) either preceding, following, or concomitantly with step (a), exposing the cells to a telomerase inhibitor comprising an oligonucleotide which is characterized by: (i) N3′→P5′ thiophosphoramidate internucleoside linkages; (ii) comprising the sequence identified as SEQ ID NO: 12; and (iii) a palmitoyl (C16) moiety linked to the 5′ terminus of the oligonucleotide via a glycerol or aminoglycerol linker wherein the carcinoma cells are breast cancer or non-small cell lung cancer cells.